-

INVESTOR ALERT: Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed Against The GEO Group, Inc. and Encourages Investors to Contact the Firm Before September 8, 2020

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of Florida on behalf of those who acquired The GEO Group, Inc. (“GEO Group” or the “Company”) (NYSE: GEO) securities during the period from February 27, 2020 through June 16, 2020 (the “Class Period”). Investors have until September 8, 2020 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) GEO Group maintained woefully ineffective COVID-19 response procedures; (ii) those inadequate procedures subjected residents of the Company's halfway houses to significant health risks; (iii) accordingly, the Company was vulnerable to significant financial and/or reputational harm; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you acquired GEO Group securities during the Class Period, have information, or would like to learn more about these claims, please contact Thomas W. Elrod of Kirby McInerney at 212-371-6600, by email at investigations@kmllp.com, or by filling out this contact form, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, and whistleblower litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney’s website: www.kmllp.com.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
(212) 371-6600
investigations@kmllp.com
www.kmllp.com

Kirby McInerney LLP

NYSE:GEO

Release Versions

Contacts

Kirby McInerney LLP
Thomas W. Elrod, Esq.
(212) 371-6600
investigations@kmllp.com
www.kmllp.com

Social Media Profiles
More News From Kirby McInerney LLP

JEFFERIES FINANCIAL GROUP, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Jefferies Financial Group, Inc. (“Jefferies” or the “Company”) (NYSE:JEF). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 25, 2026, Jefferies reported quarterly results showing weaker asset-management fees a...

ALIGNMENT HEALTHCARE, INC. INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP is investigating potential claims against Alignment Healthcare, Inc. (“Alignment Healthcare” or the “Company”) (NASDAQ:ALHC). The investigation concerns whether the Company and/or members of its senior management may have violated federal securities laws or engaged in other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On July 8, 2026, it was reported that a former executive at Alignment Healthcare fil...

UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.

NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ:UNCY) investors concerning the Company’s and/or members of its senior management’s possible violation of the federal securities laws and other unlawful business practices.[LEARN MORE ABOUT THE INVESTIGATION]What Happened?On June 30, 2026, Unicycive announced that the FDA had issued a second Complete Response Letter (“CRL”) reg...
Back to Newsroom